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Abstract: Compared to several other metal ions with similar chemical properties, zinc is 
relatively  harmless.  Only  exposure  to  high  doses  has  toxic  effects,  making  acute  zinc 
intoxication  a  rare  event.  In  addition  to  acute  intoxication,  long-term,  high-dose  zinc 
supplementation interferes with the uptake of copper. Hence, many of its toxic effects are 
in  fact  due  to  copper  deficiency.  While  systemic  homeostasis  and  efficient  regulatory 
mechanisms  on  the  cellular  level  generally  prevent  the  uptake  of  cytotoxic  doses  of 
exogenous zinc, endogenous zinc plays a significant role in cytotoxic events in single cells. 
Here, zinc influences apoptosis by acting on several molecular regulators of programmed 
cell death, including caspases and proteins from the Bcl and Bax families. One organ where 
zinc is prominently involved in cell death is the brain, and cytotoxicity in consequence of 
ischemia or trauma involves the accumulation of free zinc. Rather than being a toxic metal 
ion, zinc is an essential trace element. Whereas intoxication by excessive exposure is rare, 
zinc  deficiency  is  widespread  and  has  a  detrimental  impact  on  growth,  neuronal 
development,  and  immunity,  and  in  severe  cases  its  consequences  are  lethal.  Zinc 
deficiency  caused  by  malnutrition  and  foods  with  low  bioavailability,  aging,  certain 
diseases,  or  deregulated  homeostasis  is  a  far  more  common  risk  to  human  health  
than intoxication. 
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1. Introduction 
In the periodic table of the elements, zinc can be found in group IIb, together with the two toxic 
metals  cadmium  and  mercury.  Nevertheless,  zinc  is  considered  to  be  relatively  non-toxic  to  
humans [1]. This is reflected by a comparison of the LD50 of the sulfate salts in rats. According to the 
Toxnet database of the U.S. National Library of Medicine, the oral LD50 for zinc is close to 3 g/kg 
body  weight,  more  than  10-fold  higher  than  cadmium  and  50-fold  higher  than  mercury  [2].  An 
important factor seems to be zinc homeostasis, allowing the efficient handling of an excess of orally 
ingested  zinc,  because  after  intraperitoneal  injection  into  mice,  the  LD50  for  zinc  was  only 
approximately four-fold higher than for cadmium and mercury [3]. In contrast to the other two metals, 
for  which  no  role  in  human physiology is  known, zinc is  an essential trace element  not  only for 
humans, but  for all organisms. It is a component of more than 300 enzymes and an even greater 
number of other proteins, which emphasizes its indispensable role for human health. Optimal nucleic 
acid  and  protein  metabolism,  as  well  as  cell  growth,  division,  and  function,  require  sufficient 
availability of zinc [4].  
In this review, we will give a brief summary of zinc homeostasis, followed by a description of the 
effects of acute zinc intoxication and the consequences of long-term exposure to elevated amounts of 
zinc.  Besides  systemic  intoxication,  there  exists  evidence  for  a  physiological  involvement  of 
endogenous zinc in toxicity on the cellular level, e.g., regulating apoptosis in many different cell types, 
and having a prominent role in neuronal death. In the end, we will also briefly discuss the detrimental 
effects of zinc deficiency, because, unless they are exposed to zinc in the workplace or by accident, 
healthy individuals are at far greater risk of suffering from the adverse effects associated with zinc 
deficiency than from those associated with intoxication.  
2. Zinc Homeostasis 
The human body contains 2–3 g zinc, and nearly 90% is found in muscle and bone [5]. Other organs 
containing estimable concentrations of zinc include prostate, liver, the gastrointestinal tract, kidney, 
skin, lung, brain, heart, and pancreas [6-8]. Oral uptake of zinc leads to absorption throughout the 
small intestine and distribution subsequently occurs via the serum, where it predominately exists bound 
to several proteins such as albumin, α-microglobulin, and transferrin [9].  
On  the  cellular  level,  30–40%  of  zinc  is  localized  in  the  nucleus,  50%  in  the  cytosol  and the 
remaining  part  is  associated  with  membranes  [4].  Cellular  zinc  underlies  an  efficient  homeostatic 
control that avoids accumulation of zinc in excess (see also Figure 1a). The cellular homeostasis of 
zinc  is  mediated  by  two  protein  families;  the  zinc-importer  (Zip;  Zrt-,  Irt-like  proteins)  family, 
containing  14  proteins  that  transport  zinc  into  the  cytosol,  and  the  zinc  transporter  (ZnT)  family, 
comprising 10 proteins transporting zinc out of the cytosol [10].  
The same transporter families also regulate the intracellular distribution of zinc into the endoplasmic 
reticulum, mitochondria, and Golgi. In addition, many mammalian cell types also contain membrane-
bound vesicular structures, so-called zincosomes. These vesicles sequester high amounts of zinc and 
release it upon stimulation, e.g., with growth factors [11,12]. 
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Figure  1.  Cellular  zinc  homeostasis  and  its  impact  on  cytotoxicity  (A)  Cellular  zinc 
homeostasis is mediated by three main mechanisms. First, by transport through the plasma 
membrane by importers from the Zip-family, and export proteins from the ZnT-family. 
Second, by zinc-binding proteins such as metallothionein. Third, by transporter-mediated 
sequestration  into  intracellular  organelles,  including  endoplasmic  reticulum,  Golgi,  and 
lysosomes.  Tight  control  of  zinc  homeostasis  is  required  for  maintenance  of  cellular 
viability, whereas deregulation leads to cell death. (B) A particular role in intracellular zinc 
homeostasis is played by the metallothionein/thionein-system. Free and loosely bound zinc 
ions are bound by the apo-protein thionein (Tred), to form metallothionein (MT). Elevated 
levels  of  free  zinc  ions  can  bind  to  zinc  finger  structures  of  the  metal-regulatory 
transcription  factor  (MTF)-1,  thus  inducing  the  expression  of  thionein.  Additionally, 
oxidation  of  thiols  by  reactive  oxygen  (ROS)  or  nitrogen  (RNS)  species  triggers  the 
formation of the oxidized protein thionin (Tox) with concomitant release of zinc. 
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Finally, metallothioneins (MTs) play a significant role in zinc homeostasis by complexing up to 
20%  of  intracellular  zinc  (Figure  1b)  [13,14].  MTs  are  ubiquitous  proteins,  characterized  by  a  
low-molecular weight of 6–7 kDa, high cysteine content, and their ability to complex metal ions. One 
MT molecule can bind up to seven zinc ions. Through different affinities of the metal ion binding sites, 
it can act as a cellular zinc buffer over several orders of magnitude [15]. Dynamic regulation of cellular 
zinc by MT results from the synthesis of the apo-form thionein (T) in response to elevated intracellular 
zinc levels  by triggering the metal  response element-binding transcription  factor (MTF)-1 [16]. In 
addition, oxidation of cysteine residues can alter the number of metal binding thiols, connecting redox 
and  zinc  metabolism.  An  in-depth  discussion  of  this  complex  subject  can  be  found  in  a  recent  
review [17]. 
3. Exposure to Zinc 
There are three major routes of entry for zinc into the human body; by inhalation, through the skin, 
or by ingestion [18]. Each exposure type affects specific parts of the body (Figure 2) and allows the 
uptake of different amounts of zinc. 
3.1. Exposure by Inhalation 
Inhalation  of  zinc-containing  smoke  generally  originates  from  industrial  processes  like 
galvanization, primarily affecting manufacture workers. In addition, military smoke bombs contain 
zinc  oxide  or  zinc  chloride,  making  soldiers  a  group  in  which  several  cases  of  inhalation  of  
zinc-containing fumes were described. For example, Homma and colleagues reported a case of two 
soldiers  who  developed  adult  respiratory  distress  syndrome  (ARDS)  upon  exposure  to  a  zinc  
chloride-containing  smoke  bomb  [19].  The  two  men  died  25  and  32  days  after  the  accident, 
respectively. Another soldier was exposed to concentrated zinc chloride for several minutes during 
military training [20]. He also developed ARDS 48 h after exposure. After tracheal intubation and 
mechanical  ventilation  for  eight  days,  he  left  the  hospital,  and  four  months  after  the  incident  he 
returned to work without any respiratory disorder [20]. There are a few additional reports of related 
incidents with smoke bombs having similar effects on the respiratory tract [21,22].  
However, in none of the incidents there was unequivocal evidence that zinc was the main cause for 
the respiratory symptoms. Not only was no information about the concentrations available, but also the 
inhaled smoke contained several other ingredients besides zinc chloride. In addition, zinc chloride is 
generally caustic, so the effects could have risen from the specific properties of the compound, rather 
than being a direct effect of zinc intoxication. 
The most widely known effect of inhaling zinc-containing smoke is the so-called metal fume fever 
(MFF),  which  is  mainly  caused by inhalation of zinc oxide. This  acute syndrome is  an industrial 
disease  which  mostly  occurs  by  inhalation  of  fresh  metal  fumes  with  a  particle  size  <1  µm  in 
occupational situations such as zinc smelting or welding [23]. Symptoms of this reversible syndrome 
begin generally a few hours after acute exposure and include fever, muscle soreness, nausea, fatigue, 
and respiratory effects like chest pain, cough, and dyspnea [24]. The respiratory symptoms have been 
shown  to  be  accompanied  by  an  increase  in  bronchiolar  leukocytes  [23].  In  general,  MFF  is  not  
life-threatening and the respiratory effects disappear within one to four days [25].  Int. J. Environ. Res. Public Health 2010, 7                 
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Development of MFF is connected to the exposure level, but very little data is available concerning 
the  zinc  concentrations  that  trigger  this  syndrome  [26].  Two  volunteers  developed  MFF  as  a 
consequence of acute inhalation (10–12 minutes) of 600 mg zinc/m
3 as zinc oxide [27]. Hammond and 
colleagues reported about workers who had shortness of breath and chest pain 2–12 hours following 
exposure to 320–580 mg zinc/m
3 as zinc oxide [28]. Only small changes in forced expiratory flow 
were observed after exposure to 77 mg zinc/m
3 (15–30 minutes) as zinc oxide [29]. Several reports of 
exposures to lower concentrations of zinc oxide (14 mg/m
3 for eight hours, 8–12 mg zinc/m
3 for up to 
three hours and 0.034 mg zinc/m
3 for six to eight hours) did not result in symptoms of metal fume 
fever  [28,30,31].  Today,  the  permissible  exposure  limit  according  to  the  Occupational  Safety  and 
Health Administration (OSHA) is 5 mg/m
3 for zinc oxide (dusts and fumes) in workplace air during an 
8-hour workday, 40-hour work week [32]. 
Figure 2. Comparison of the effects of zinc intoxication versus deficiency. Intoxication by 
excessive  exposure  to,  or  intake  of,  zinc  (left  hand  side),  and  deprivation  of  zinc  by 
malnutrition or medical conditions (right hand side), have detrimental effects on different 
organ  systems.  Effects  that  could  not  be attributed to  a certain  organ system  or affect 
several organs are classified as systemic symptoms.  
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3.2. Dermal Exposure 
Dermal absorption of zinc occurs, but the number of studies is limited and the mechanism is still not 
clearly defined. Agren and colleagues pointed out that the pH of the skin, the amount of zinc applied, 
and its chemical speciation influence the absorption of zinc [33,34].  
In a study in which a 25% zinc oxide patch (2.9 mg/cm
2) was placed on human skin for 48 hours, 
there  was  no  evidence  of  dermal  irritation  [33].  In  another  study  comparing  the  dermal  effect  of 
different zinc compounds in mice, rabbits, and guinea pigs, zinc chloride was clearly the strongest 
irritant, followed by zinc acetate, causing moderate, and zinc sulfate, causing low irritations. Consistent 
with the study by Agren, zinc oxide did not show any irritant effect on skin [35].  
As mentioned above, zinc chloride is caustic, and the irritation does not necessarily indicate a toxic 
effect of zinc. In contrast to a potentially harmful effect of zinc on skin, it should be noted that zinc is a 
well-known  supplement  for  topical  treatment  of  wounds  and  several  dermatological  
conditions [34,36-38]. Based on the existing data, it can be concluded that dermal exposure to zinc 
does not constitute a noteworthy toxicological risk. 
3.3. Oral Exposure 
Due to its nature as an essential trace element, oral uptake of small amounts of zinc is essential for 
survival. The recommended dietary allowance (RDA) for zinc is 11 mg/day for men and 8 mg/day for 
women [39]. Lower zinc intake is recommended for infants (2–3 mg/day) and children (5–9 mg/day) 
because of their lower average body weights [39]. This is significantly below the LD50 value, which 
has been estimated to be 27 g zinc/day humans based on comparison with equivalent studies in rats and 
mice [18]. In general, uptake of such an amount is unlikely, because approximately 225–400 mg zinc 
have been determined to be an emetic dose [40]. However, there is one published report of a woman 
who died after oral intake of 28 g zinc sulfate. After ingestion, she started vomiting and developed 
tachycardia as well as hyperglycemia. She died five days later of hemorrhagic pancreatitis and renal 
failure [41]. 
Immediate symptoms after uptake of toxic amounts of zinc include abdominal pain, nausea, and 
vomiting.  Additional  effects  include  lethargy,  anemia,  and  dizziness  [42].  Particular  effects  of 
excessive oral zinc exposure are discussed in detail below. 
Gastrointestinal Effects 
The gastrointestinal tract is directly affected by ingested zinc, before it is distributed through the 
body.  Therefore,  multiple  gastrointestinal  symptoms  after  oral  uptake  of  zinc  have  been  reported. 
Brown et al. described several cases in which high zinc ingestion resulted from storage of food or drink 
in galvanized containers. Ingestion was caused by the moderately acidic nature of the food or drink, 
enabling the removal of sufficient zinc from the galvanized coating. The resulting symptoms included 
nausea and vomiting, epigastric pain, abdominal cramps, and diarrhea [40]. 
In a study by Samman and Roberts, symptoms such as abdominal cramps, vomiting and nausea 
occurred in 26 of 47 healthy volunteers following ingestion of zinc sulfate tablets, containing 150 mg Int. J. Environ. Res. Public Health 2010, 7                 
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elemental  zinc,  for  six  weeks  [43].  However,  similar  doses  have  been  used  in  several  other  zinc 
supplementation studies without comparable side effects [44]. 
In addition to zinc sulfate, other zinc compounds like zinc oxide and zinc gluconate also have a 
similar impact on the gastrointestinal system [45-47]. A 39-year-old man showed nausea, vomiting, 
and abdominal pain six hours after ingesting 150 g of a 10% zinc oxide lotion, but without signs of 
systemic toxicity. Furthermore, he developed gastroduodenal corrosive injury. The symptoms persisted 
for  three  days  and  on  the  fifth  day  of  admission,  the  corrosive  injury  showed  regression  
without cicatrization [47].  
Zinc-Induced Copper Deficiency 
Taking up large doses of supplemental zinc over extended periods of time is frequently associated 
with copper deficiency [48-50]. This correlation seems to be caused by the competitive absorption 
relationship  of  zinc  and  copper  within  enterocytes,  mediated  by  MT.  The  expression  of  MT  is 
upregulated  by  high  dietary  zinc  content,  and  MT  binds  copper  with  a  higher  affinity  than  zinc. 
Consequently,  available  copper  ions  are  bound  by  MT  and  the  resulting  complex  is  subsequently 
excreted [51,52]. Oestreicher and Cousins stated that the dietary intake of different doses of copper and 
zinc did not significantly alter the absorption of the other metal, as long as they were given at the same 
ratio,  irrespective  if  1  mg/kg  copper  and  5  mg/kg  zinc,  or  up  to  36  mg/kg  copper  together  with  
180 mg/kg zinc were given [53]. Nevertheless, copper absorption is depressed when zinc is given in 
high excess over copper [54]. 
Frequent  symptoms  of  copper  deficiency  include  hypocupremia,  impaired  iron  mobilization, 
anemia, leukopenia, neutropenia, decreased superoxide dismutase (SOD) (particularly erythrocyte SOD 
(ESOD)),  ceruloplasmin  as  well  as  cytochrome-c  oxidase,  but  increased  plasma  cholesterol  and 
LDL:HDL cholesterol and abnormal cardiac function [55-57]. 
Furthermore,  Irving  and  colleagues  reported  the  case  of  a  19-year  old  woman  who  was 
supplemented with two doses of 50 mg zinc per day as part of a treatment of Hallervorden–Spatz
 
syndrome,  leading  to  a  total  daily  intake  of  about  121.25  mg  of  zinc  for  more  than  5  years, 
corresponding to approximately 15 times the RDA. Her daily intake of copper was 2 mg, which was 
approximately twice the RDA. As a result, she was markedly anemic and had severe neutropenia. Zinc-
induced copper deficiency was confirmed by elevated serum zinc and low copper and ceruloplasmin 
serum levels. Four weeks after zinc therapy was stopped, all hematological and trace-metal parameters 
showed strong trends toward normalization and were normal after eight months [58].  
Prasad  and  colleagues  reported  several  cases  of  patients  with  sickle  cell  anemia  who  received  
150 mg zinc/day and consequently showed low plasma copper, low ceruloplasmin, leukopenia, and  
anemia [59]. Another case report described a 31-year-old schizophrenic man who had been ingesting 
coins  for  10  years  [60].  He  entered  the  hospital  with  symptoms  including  nausea,  vomiting,  and 
abdominal pain. Furthermore, profound anemia, neutropenia, and virtually absent serum copper and 
ceruloplasmin levels together with elevated zinc levels were diagnosed. Upon X-ray examination a 
large number of coins (totaling $22.50) were identified and surgically removed. Following the surgery, 
anemia and copper deficiency rapidly resolved. His copper deficiency was attributed to the ingestion of 
pennies, which since 1982 are composed of 98% zinc and 2% copper [60]. Several additional reports Int. J. Environ. Res. Public Health 2010, 7                 
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of zinc-induced copper deficiency leading to anemia and several other cytopenias were reviewed by 
Fiske and colleagues [55]. 
The mechanism by which copper deficiency induces anemia is based on the requirement of copper 
for several enzymes involved in iron transport and utilization and, therefore, in heme synthesis. For 
example, ceruloplasmin is a ferroxidase that binds copper and converts ferrous to ferric iron, allowing 
it to bind to transferrin and be transported. Cytochrome-c oxidase is also dependent on copper, and is 
required for the reduction of ferric iron to be incorporated into the heme molecule [61-63]. In addition 
to interference with heme synthesis, copper deficiency causes approximately 85% reduction of ESOD 
in the red blood cell (RBC) membrane, decreasing RBC survival time [64].  
Whereas  a  recent  meta-analysis  found  no  general  effect  of  zinc  supplementation  on  serum 
lipoproteins [65], it may occur as a consequence of disturbed copper homeostasis. Copper deficiency is 
related to alterations of serum cholesterol levels [57]. In healthy men, a daily intake of 160 mg zinc/day 
decreased HDL cholesterol significantly [66,67]. Also, young women who ingested 100 mg zinc/day 
showed a reduction in HDL cholesterol [68]. A study with 24 men who were fed omnivorous diets that 
were deficient in copper (0.89 mg) and high in zinc (21.4 mg), i.e., a Zn:Cu ratio of 23.5, showed low 
plasma copper, ESOD and HDL cholesterol, while LDL cholesterol was elevated [69]. This study was 
stopped  after  11  weeks  because  four  participants  experienced  cardiac  abnormalities.  Klevay  and 
colleagues fed one man an omnivorous diet providing a Zn to copper ratio ≥ 16 for 105 days. Plasma 
copper and ceruloplasmin decreased, whereas total cholesterol and LDL cholesterol increased [70]. 
This experiment was ended when arrhythmia was detected. Taking into account several additional 
studies,  Sandstead  suggested  that  cardiac  abnormalities  were  associated  with  Zn  to  copper  
ratios ≥16 [57].  
Zinc Supplementation and Cancer 
Whereas several other metals are well-known carcinogens, zinc is not generally considered to be a 
causative agent for cancer development. In contrast, displacement of zinc from zinc-binding structures, 
e.g., finger structures in DNA repair enzymes, may even be a major mechanism for carcinogenicity of 
other metals such as cadmium, cobalt, nickel, and arsenic [71]. 
One  well  investigated  example  in  which  an  involvement  of  zinc  in  cancer  development  was 
suggested is prostate cancer. Notably, zinc levels in prostate adenocarcinoma are significantly lower 
than in the surrounding normal prostate tissues, suggesting an implication of zinc in the pathogenesis 
and  progression  of  prostate  malignancy  [72-74].  This  is  based  on  a  down  regulation  of  the  zinc 
transporter Zip1, which is responsible for zinc uptake and accumulation in prostate cells [75,76].  
Men with moderate to higher zinc intake may have a lower risk for prostate cancer, but the opposite 
may be true at extremely high doses and long-term supplementation [77]. A study by Leitzmann and 
colleagues examined the association between supplemental zinc intake and prostate cancer risk among 
46,974 U.S. men. During 14 years, 2901 new cases of prostate cancer were observed, of which 434 
were diagnosed as advanced cancer. Supplemental zinc intake at doses of up to 100 mg/day did not 
cause a higher prostate cancer risk, whereas long-term supplementation with higher doses increased the 
relative risk 2.9-fold [78]. This increased risk may not be due to direct carcinogenicity of zinc, because Int. J. Environ. Res. Public Health 2010, 7                 
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it is known that immunosuppression significantly increases the incidence of cancer, and, as discussed 
in the following paragraph, high doses of zinc can be immunosuppressive. 
Immunological Effects 
Sufficient availability of zinc is of particular importance to the immune system. Thereby, it plays a 
key role in multisided cellular and molecular mechanisms [79,80]. For instance, zinc influences the 
lymphocyte  response  to  mitogens  and  cytokines,  serves  as  a  co-factor  for  the  thymic  hormone 
thymulin, and is involved in leukocyte signal transduction [81-83]. An influence of zinc excess on T 
cell function was observed in several in vitro studies. In cell culture, very high zinc concentrations 
(above 100 µM) in a serum-free culture medium stimulate monocytes to secrete pro-inflammatory 
cytokines  [84], but actually inhibit T cell functions. In general, T cells have a lower intracellular zinc 
concentration and are more susceptible to increasing zinc levels than monocytes [85,86]. Also, in vitro 
alloreactivity was inhibited in the mixed lymphocyte reaction (MLC) after treatment with more than  
50 µM zinc [87]. A similar inhibition was observed when the MLC was done ex vivo with cells from 
individuals that had been supplemented with 80 mg zinc per day for one week, indicating that zinc 
supplementation  has  the  potential  to  suppress  the  allogeneic  immune  response  at  relatively  low  
doses [88]. 
An in vivo study supported the finding that zinc excess can affect lymphocyte function. 83 healthy 
volunteers  ingested  330  mg  zinc/  day  in  three doses for  a month. The treatment  had a small but 
significant  influence  on  the  lymphocyte  response  to  the  mitogens  phytohemagglutinin  (PHA)  and 
Concanavalin A (Con A). Interestingly, it was observed that zinc had an immuno-regulatory influence, 
i.e.,  it  decreased  the  lymphocyte  response  in  high  responders  and  had  an  enhancing  effect  on  
low responders [89].  
4. The Role of Zinc in Cell Death 
In addition to the systemic toxic effects of zinc, this metal is also involved in the regulation of live 
and death decisions on the cellular level. First, we will discuss its role in apoptosis. Second, we will 
focus on an organ where zinc toxicity has been investigated in great detail, the brain. 
4.1. Impact of Zinc on Apoptosis  
The exact role of zinc in the regulation of apoptosis is ambiguous. A variety of studies indicate that, 
depending on its concentration, zinc can either be pro- or anti-apoptotic, and both, zinc deprivation and 
excess, can induce apoptosis in the same cell line [90-93]. 
The induction of apoptosis by high levels of intracellular zinc has been shown in different tissues 
and cell types [93-95]. Reports indicate that accumulation of intracellular zinc, either as a consequence 
of  exogenous  administration  or  release  from  intracellular  stores  by  reactive  oxygen  species  or 
nitrosation,  activates  pro-apoptotic  molecules  like  p38  and  potassium  channels,  leading  to  cell  
death [93,96-98]. Increased intracellular zinc levels may also induce cell death by inhibition of the 
energy metabolism [99,100]. Int. J. Environ. Res. Public Health 2010, 7                 
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Sensitive  targets  of  zinc  toxicity  are  the  anti-apoptotic  Bcl-2-like  and  pro-apoptotic  Bax-like 
mitochondrial membrane proteins. In context of its apoptosis-inducing properties, zinc has been shown 
to increase the expression of Bax, leading to a decrease in the Bcl-2/Bax ratio [101]. As a consequence, 
dissipation  of  the  mitochondrial  membrane  potential  leads  to  the  release  of  cytochrome-c  from 
mitochondria into the cytosol [96,102-105].  
The anti-apoptotic properties of zinc likely comprise two main mechanisms. First, zinc limits the 
extent of damage induced during oxidative stress, thereby suppressing signaling pathways resulting in 
apoptosis. Second, zinc directly affects several proteins and pathways that regulate apoptosis.  
Consistent with the first issue, zinc deficiency has been shown to induce oxidative stress [106-108]. 
Mechanisms by which the redox-inert zinc protects cells against oxidative damage seem to include its 
property to protect sulfhydryl groups in proteins from oxidation [109]. Furthermore, by stabilizing 
lipids and proteins, zinc can preserve cellular membranes and macromolecules from oxidative damage. 
On the other hand, it has to be noted that elevated availability of zinc may also induce oxidative stress, 
and  its  impact  on  redox  homeostasis  may  either  be  protective  or  promoting,  depending  on  its 
availability [17]. 
With  regard  to  the  second  mechanism,  interaction  of  zinc  with  several  apoptosis-regulating 
molecules  has  been  reported.  Zinc  is  a  potent  caspase-3  inhibitor  [110]  with  an  IC50  below  
10 nM [111]. Furthermore, inhibition of caspases-6, -7, and -8 at low zinc concentrations was also 
shown, with caspase-6 being the most sensitive of the three [112].  
Zinc deficiency can also induce apoptosis by disrupting growth factor signaling molecules such as 
ERK  and  Akt  [113].  Other  molecular  targets  for  zinc  are  the  anti-apoptotic  Bcl-2-like  and  pro-
apoptotic Bax-like mitochondrial membrane proteins. Zinc has been shown to increase the Bcl-2/Bax 
ratio, thereby increasing the resistance of the cells to apoptosis [114]. Consistent with this, in a study 
by Zalewski and colleagues apoptosis was induced in premonocytic cells by treatment with hydrogen 
peroxide.  Supplementation  with  1  mM  zinc  increased  the  ratio  of  Bcl-2  to  Bax  resulting  in  the 
inhibition of active caspase-3 and reduction of apoptosis [115]. Zinc-mediated apoptosis is abrogated 
by chelation with TPEN [116]. This is not undisputed, because it has also been shown in another study 
that zinc can increase the expression of Bax, leading to an decreased Bcl-2/Bax ratio and the release of 
cytochrome-c from mitochondria [101].  
The influence of zinc on apoptosis is very complex and data are in part even contradictory. Amongst 
others, variables in this complex network are tissue and cell type, zinc concentration, expression of 
zinc  transporters  and  zinc-binding  proteins,  other  environmental  circumstances  like  oxidative  or 
nitrosative stress, and the involvement of multiple molecular targets with opposing functions.  
4.2. Role of Zinc in Neuronal Death  
A  prominent  and  well investigated example for the control  that zinc exerts on survival  on the 
cellular level is the brain. This will now be discussed in more detail as an example of the mechanisms 
by which zinc can influence cellular survival. 
Normally, homeostatic mechanisms should prevent zinc from accumulating in the brain to reach 
toxic concentrations as a result of excessive oral ingestion. However, there are reports of neurological Int. J. Environ. Res. Public Health 2010, 7                 
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symptoms  following zinc intoxication, e.g., of a boy who showed lethargy and focal  neurological 
deficits three days after he ingested 12 g of metallic zinc [117].  
Many  studies  indicate  that  zinc  acts  as  a  neuromodulator  [118-121].  On  the  other  hand, 
experimental  evidence  indicates  that  endogenous  zinc  might  be  a  relatively  potent,  rapidly  acting 
neurotoxin, and, to a lesser extent, also a gliotoxin [122-126].  
Zinc is stored in and released from vesicles in presynaptic terminals of a specific subset of neurons 
that also releases glutamate. Therefore, these neurons are defined as ”gluzinergic” neurons [119, 127]. 
Zinc can be released from  presynaptic terminals during synaptic transmission, enabling it to enter 
postsynaptic somata and dendrites  of cells  via zinc-permeable ion  channels [105]. These channels 
include  NMDA  (N-methyl-D-aspartate)-gated  channels  [128],  voltage-gated  calcium  
channels  [129,130]  and  the  calcium-permeable  AMPA  (α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid)/kainate channel [131,132]. 
In addition to being sequestered in vesicles of presynaptic terminals in the gluzinergic neurons, zinc 
can  also  be  bound  to  MT,  especially  MT-III,  in  perikarya  as  well  as  being  taken  up  by  
mitochondria  [133].  The  MT-III  isoform  is  found  only  in  the  brain  and  it  is  abundant  in  the  
gluzinergic neurons [134,135].  
Exposure to 300–600 µM zinc for 15 minutes results in extensive neuronal death in cortical cell 
culture [136]. Considering that neurons store high amounts of free zinc in their terminals [137] that are 
released upon depolarization [138,139], zinc may play an active role in neuronal injury. Furthermore, 
membrane  depolarization,  which  is  associated  with  acute  brain  injury  [140],  greatly  increases  the 
potency of zinc to act as a neurotoxin [141]. Weiss et al. confirmed this by showing that depolarization 
with high concentrations (25 mM) of potassium media requires just a five minute-exposure to 100 µM 
zinc to kill all neurons in cortical cell culture [131].  
Zinc has been described as a critical component of the excitotoxic cascade occurring after ischemia, 
seizures, and head trauma [141-143]. The first study providing evidence that zinc accumulation may 
play a role in the selective death of dentate hilar neurons after global ischemia in rats was done by 
Tonder and colleagues [144]. In the meantime, zinc accumulation in dying or dead neurons has not 
only been shown in the hippocampal hilar region, but also in all brain regions damaged in global 
ischemia  such  as  hippocampal CA1, neocortex, thalamus,  and striatum  [145]. Consistent  with  the 
hypothesis that zinc-accumulation may lead to neuronal cell death, this event was prevented by the 
intraventricular injection of the zinc-chelating agent CaEDTA [145].  
Zinc release and accumulation of zinc ions was also observed in a rat model of traumatic brain 
injury, where Suh and colleagues showed that trauma is associated with loss of zinc from presynaptic 
boutons and appearance of zinc in injured neurons. Again, neuroprotection occurred by intraventricular 
administration of a zinc chelator [146].  
For some time, vesicular zinc was thought to be the only releasable pool of zinc in the brain [127]. 
This led to the assumption that the zinc ions accumulating in injured neurons must be entirely of 
presynaptic  origin  [127],  but  when  ZnT-3  knock-out  mice  were  investigated,  which  lack 
histochemically reactive zinc in synaptic vesicles, they still showed zinc accumulation in degenerating 
neurons, pointing toward sources other than synaptic vesicular zinc [147]. Alternative dynamic zinc 
sources might be MT-III as well as mitochondrial stores in the postsynaptic neurons [148,149].  Int. J. Environ. Res. Public Health 2010, 7                 
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Although zinc is redox-inactive in biological systems and exists only as a bivalent cation, there is 
evidence that zinc toxicity in neurons is mediated mainly by oxidative stress [141]. Zinc-induced cell 
death is associated with increased levels of reactive oxygen species in neurons [150,151]. In addition, 
free-radical-generating  enzymes  like  NADPH  oxidase  are  induced  and  activated  by  exposure  to  
zinc  [152].  Finally,  zinc-induced  cell  death  has  been  shown  to  be  attenuated  by  various  
antioxidant interventions [96,153].  
Besides  oxidative  stress,  nitrosative  stress  can  also  affect  zinc-induced  neuronal  injury.  Nitric 
monoxide plays a crucial role in zinc toxicity by releasing zinc ions from MT  [154], and inhibition of 
nitric oxide synthase significantly reduces zinc release from brain slices during oxygen and glucose 
deprivation [155]. Consistent with this, Frederickson and colleagues observed that nitric oxide also 
rapidly releases zinc from presynaptic terminals [156].  
In addition to the impact of zinc on apoptosis discussed above, zinc-induced apoptosis in neurons 
might be based on two additional mechanisms. First, zinc-exposed neurons show an induction of the 
neutrophin receptor p75
NTR and p75
NTR-associated death executor (NADE) [157], a combination that 
can  trigger  caspase  activation  and  apoptosis  [158].  Second,  high  intracellular  zinc  concentrations 
trigger dysfunction of neuronal mitochondria, resulting in the release of pro-apoptotic proteins such as 
cytochrome-c and apoptosis-inducing factor (AIF) [148]. 
Although the release of intracellular zinc triggers neuronal apoptosis [96,159,160], indicators of 
necrosis  such  as  cell  body  swelling  and  destruction  of  intracellular  organelles  have  also  been  
observed [96,150], indicating that zinc-induced neuronal cell death might encompass both apoptotic 
and  necrotic  mechanisms  [143].  Taken  together,  alterations  of  neuronal  zinc  homeostasis  have  a 
profound  influence  on  cellular  survival  during  acute  insults,  and  zinc  chelators  are  discussed  as 
potential therapeutic agents for the treatment of stroke [161]. 
It seems likely that zinc is also involved in neurodegenerative diseases, e.g., zinc and a deregulated 
zinc homeostasis could be important to onset and progression of Alzheimer’s disease [162]. Here, the 
use  of  metal  chelators  such  as  clioquinol to  restore normal  neuronal  zinc homeostasis  has  shown 
promising results in vivo [163]. 
5. Zinc Deficiency 
As discussed above, systemic zinc toxicity is not a major health problem. On the other hand, due to 
its essentiality, a lack of this trace element leads to far more severe and widespread problems. Both, 
nutritional and inherited zinc deficiency generate similar symptoms [164], and clinical zinc deficiency 
causes a spectrum from mild and marginal effects up to symptoms of severe nature (Figure 2) [165].  
Human  zinc  deficiency  was  first  reported  in  1961,  when  Iranian  males  were  diagnosed  with 
symptoms  including  growth  retardation,  hypogonadism,  skin  abnormalities,  and  mental  lethargy, 
attributed  to  nutritional  zinc  deficiency  [166].  Later  studies  with  some  Egyptian  patients  showed 
remarkably similar clinical features [167]. Additional studies in the ongoing years manifested zinc 
deficiency as a potentially widespread problem in developing as well as in industrialized nations [168].  
Severe zinc deficiency can be either inherited or acquired. The most severe of the inherited forms is 
acrodermatitis enteropathica, a rare autosomal recessive metabolic disorder resulting from a mutation 
in the intestinal Zip4 transporter [169]. Symptoms of this condition include skin lesions, alopecia, Int. J. Environ. Res. Public Health 2010, 7                 
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diarrhea,  neuropsychological  disturbances,  weight  loss,  reduced  immune  function,  as  well  as 
hypogonadism in men, and can be lethal in the absence of treatment [170].  
Acquired severe zinc deficiency has been observed in patients receiving total parental nutrition 
without supplementation of zinc, following excessive alcohol ingestion, severe malabsorption, and 
iatrogenic causes such as treatment with histidine or penicillamine [165]. The symptoms are mostly 
similar to those arising during acrodermatitis enteropathica. 
Some reports indicate the existence of another group of inherited disorders of zinc metabolism. 
They  lead  to  baseline  zinc  plasma  levels  above  300  µg/100  mL,  more  than  three  times  the 
physiological level, while iron and copper levels stay normal [171-173]. Even though this exceeds the 
amount normally found in serum after zinc intoxication, symptoms range from none to severe anemia, 
growth failure, and systemic inflammation, and resemble zinc deficiency rather than chronic or acute 
intoxication [172-175]. The elevated zinc levels have been attributed to excessive binding to serum 
proteins,  e.g.,  by  albumin  [171,173],  or  to  overexpression  of  the  zinc-binding  S100  protein  
calprotectin [172,174]. Hence, the large amounts of zinc in the serum of these patients are sequestered 
by proteins, potentially even depleting biologically available zinc [175].  
Clinical manifestations of moderate zinc deficiency are mainly found in patients with low dietary 
zinc intake, alcohol abuse, malabsorption, chronic renal disease, and chronic debilitation. Symptoms 
include growth retardation (in growing children and adolescents), hypogonadism in men, skin changes, 
poor appetite, mental lethargy, delayed wound healing, taste abnormalities, abnormal dark adaptation, 
and anergy [165]. 
Moderate  zinc  deficiency  can  also  occur  as  a  consequence  of  sickle  cell  disease  [176]. 
Hyperzincuria and a high protein turnover due to increased hemolysis lead to moderate zinc deficiency 
in  these  patients,  which  causes  clinical  manifestations  typical  for  zinc  deficiency,  such  as  growth 
retardation, hypogonadism in males, hyperammonemia, abnormal dark adaptation, and cell-mediated 
immune disorder [177] connected with thymic atrophy [178]. 
In  mild  cases  of  zinc  deficiency,  slight  weight  loss,  oligospermia  and  hyperammonemia  were 
observed [165]. One population in which mild zinc deficiency occurs with high prevalence, even in 
industrialized countries, are the elderly. Here, a significant proportion has reduced serum zinc levels, 
and zinc supplementation studies indicate that this deficiency contributes significantly to increased 
susceptibility to infectious diseases [44].  
The overall frequency of zinc deficiency worldwide is expected to be higher than 20% [179]. In 
developing countries, it may affect more than 2 billion people [166,180-182]. Furthermore, it has been 
estimated  that  only  42.5%  of  the  elderly  (≥71  years)  in  the  Unites  States  have  adequate  zinc  
intake [183]. This widespread occurrence combined with the variety of clinical manifestations makes 
zinc deficiency a serious nutritional problem, which has a far greater impact on human health than the 
relatively infrequent intoxication with zinc.  
6. Conclusions 
Zinc is an essential trace element, and the human body has efficient mechanisms, both on systemic 
and cellular levels, to maintain homeostasis over a broad exposure range. Consequently, zinc has a Int. J. Environ. Res. Public Health 2010, 7                 
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rather low toxicity, and a severe impact on human health by intoxication with zinc is a relatively  
rare event. 
Nevertheless, on the cellular level zinc impacts survival and may be a crucial regulator of apoptosis 
as well as neuronal death following brain injury. Although these effects seem to be unresponsive to 
nutritional  supplementation  with  zinc,  future  research  may  allow  influencing  these  processes  via 
substances that alter zinc homeostasis, instead of directly giving zinc. 
Whereas there are only anecdotal reports of severe zinc intoxication, zinc deficiency is a condition 
with broad occurrence and potentially profound impact. Here, the application of “negative zinc”, i.e., 
substances or conditions that deplete the body of zinc, constitute a major health risk. The impact ranges 
from mild zinc deficiency, which can aggravate infections by impairing the immune defense, up to 
severe cases, in which the symptoms are obvious and cause reduced life expectancy. 
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